Sarepta Therapeutics (NASDAQ:SRPT) Receives Sell Rating from HC Wainwright

Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “sell” rating reissued by research analysts at HC Wainwright in a report released on Thursday,Benzinga reports. They currently have a $75.00 target price on the biotechnology company’s stock. HC Wainwright’s target price indicates a potential downside of 37.63% from the stock’s previous close.

A number of other brokerages have also issued reports on SRPT. William Blair raised Sarepta Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. Royal Bank of Canada restated an “outperform” rating and issued a $182.00 target price on shares of Sarepta Therapeutics in a research note on Monday, October 21st. Piper Sandler decreased their price target on Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a research note on Wednesday, November 27th. Guggenheim boosted their price objective on Sarepta Therapeutics from $148.00 to $150.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Finally, Evercore ISI decreased their target price on Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. One analyst has rated the stock with a sell rating, two have given a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $178.71.

Sarepta Therapeutics Stock Performance

NASDAQ:SRPT opened at $120.25 on Thursday. The firm’s fifty day simple moving average is $123.46 and its 200 day simple moving average is $131.44. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics has a twelve month low of $89.92 and a twelve month high of $173.25. The firm has a market capitalization of $11.49 billion, a price-to-earnings ratio of 96.20 and a beta of 0.77.

Insider Activity at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 1,636 shares of the firm’s stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $125.55, for a total value of $205,399.80. Following the completion of the transaction, the director now directly owns 5,880 shares in the company, valued at $738,234. This trade represents a 21.77 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the completion of the sale, the director now owns 22,840 shares of the company’s stock, valued at approximately $2,851,345.60. This trade represents a 31.49 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 7.70% of the company’s stock.

Institutional Investors Weigh In On Sarepta Therapeutics

Hedge funds have recently bought and sold shares of the business. Innealta Capital LLC purchased a new stake in shares of Sarepta Therapeutics in the second quarter worth approximately $31,000. Nkcfo LLC purchased a new stake in Sarepta Therapeutics in the 2nd quarter worth approximately $43,000. Sunbelt Securities Inc. boosted its stake in shares of Sarepta Therapeutics by 446.2% during the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 232 shares during the period. Huntington National Bank grew its holdings in shares of Sarepta Therapeutics by 150.9% during the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 175 shares in the last quarter. Finally, Riggs Asset Managment Co. Inc. increased its stake in shares of Sarepta Therapeutics by 33.3% in the second quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company’s stock worth $47,000 after acquiring an additional 75 shares during the last quarter. 86.68% of the stock is owned by hedge funds and other institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.